Kalaris Therapeutics, Inc.

KLRS · XNAS

CIK 1754068fmd_1VE18HN42S6FJJ79CCZ1J8KC88Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.